Summit Therapeutics Business Summary

Summit Therapeutics Inc. (SMMT) is a clinical-stage biopharmaceutical oncology company that generates revenue primarily through strategic licensing agreements, clinical trial collaborations, and potential future product commercialization. The company’s business model is centered on the development of its lead candidate, ivonescimab, a potential first-in-class bispecific antibody that simultaneously blocks PD-1 and VEGF to target the tumor microenvironment. As of February 2026, the company’s primary segment is oncology, specifically targeting non-small cell lung cancer (NSCLC) and colorectal cancer. Following the FDA’s January 2026 acceptance of its Biologics License Application (BLA) for ivonescimab in EGFR-mutated NSCLC, the company is transitioning toward a commercial-stage entity with a PDUFA goal date of November 14, 2026. Summit competes directly with global pharmaceutical giants such as Merck & Co. (Keytruda), AstraZeneca (Tagrisso/Imfinzi), and Bristol Myers Squibb (Opdivo), positioning itself as a disruptive challenger aiming to establish a new standard of care by outperforming established PD-1 monotherapies in head-to-head clinical efficacy. The leadership team is anchored by Co-CEO and Executive Chairman Robert W. Duggan and Co-CEO and President Dr. Maky Zanganeh, both of whom previously led Pharmacyclics to a $21 billion acquisition by AbbVie. Manmeet Soni serves as the Chief Operating Officer and Chief Financial Officer, bringing a pedigree from Reata Pharmaceuticals and Alnylam, while Dr. Allen S. Yang leads clinical development as the Chief R&D Strategy Officer. The company was co-founded in 2003 by renowned geneticist Dame Kay Davies. Summit’s board of directors features high-profile industry veterans, including Dr. Yu (Michelle) Xia, the founder and CEO of Akeso, Inc., and Dr. Mostafa Ronaghi, the former Chief Technology Officer of Illumina and co-founder of GRAIL. Notable institutional backing includes significant positions from T. Rowe Price and Vanguard, alongside majority ownership by Robert Duggan, who maintains a roughly 74% stake in the company.